Savvy Advisors Inc. Acquires 21,107 Shares of Bristol-Myers Squibb (NYSE:BMY)

Savvy Advisors Inc. increased its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 437.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,930 shares of the biopharmaceutical company's stock after buying an additional 21,107 shares during the quarter. Savvy Advisors Inc.'s holdings in Bristol-Myers Squibb were worth $1,467,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Fairway Wealth LLC bought a new position in Bristol-Myers Squibb in the fourth quarter worth $28,000. Comprehensive Financial Planning Inc. PA bought a new position in Bristol-Myers Squibb during the fourth quarter worth about $34,000. Westend Capital Management LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $38,000. Tacita Capital Inc acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at $39,000. Finally, M Holdings Securities Inc. bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at $39,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Insiders Place Their Bets

In other news, EVP Samit Hirawat bought 1,823 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.07% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on BMY shares. UBS Group cut their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. Truist Financial boosted their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Wells Fargo & Company upped their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Finally, Citigroup boosted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $57.67.

Bristol-Myers Squibb Stock Down 0.3 %

BMY traded down $0.13 during trading on Friday, reaching $49.24. The company had a trading volume of 14,244,048 shares, compared to its average volume of 12,969,441. The business's fifty day moving average price is $57.11 and its 200 day moving average price is $56.66. The company has a market cap of $100.18 billion, a P/E ratio of -11.14, a PEG ratio of 2.07 and a beta of 0.41. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Equities analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 5.04%. Bristol-Myers Squibb's dividend payout ratio is -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.